Posted by Michael Wonder on 25 Nov 2023
Jazz Pharmaceuticals receives Health Canada approval for Epidiolex (cannabidiol oral solution) for the treatment of seizures associated with three rare forms of epilepsy
23 November 2023 - Jazz Pharmaceuticals Canada today announced that Epidiolex (cannabidiol oral solution), has been approved by Health Canada for use as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex in patients 2 years of age and older.
These three conditions are rare and severe forms of epilepsy that cause multiple seizure types, which are generally resistant to treatment.
